T Thum1, J Borlak. 1. Fraunhofer Institute of Toxicology and Aerosol Research, Department of Molecular Toxicology and Pharmacokinetics, Hannover, Germany.
Abstract
BACKGROUND: Cytochrome P450 mono-oxygenases bring about metabolism of many drugs, including verapamil, but no information is available on the metabolism of such drugs in the human heart. METHODS: We investigated the gene expression of major human cytochrome P450 mono-oxygenases in the various regions of explanted hearts from six patients with dilated cardiomyopathy and one with transposition of the arterial trunk. For comparison we also studied samples of liver and lung from three patients and two samples of normal heart. The biological significance of tissue-specific cytochrome mono-oxygenase gene expression was further investigated by study of the microsomal metabolism of verapamil in ventricular tissue. FINDINGS: mRNA for the cytochromes 1A1, 2B6/7, 2C8-19, 2D6, and 4B1 was predominantly expressed in the right ventricle; the unilateral expression of the 2D6 gene in right-venticular tissue is important because of its key role in the metabolism of beta-blockers. A strong correlation between tissue-specific gene expression and enzyme activity was found; microsomal metabolism of verapamil was confined to the right ventricle. By contrast, cytochrome P450 3A genes (which are the major drug-metabolising enzymes in the liver and the lung) were not expressed in any of the human heart tissues, and mRNA transcripts for epoxide hydrolase, cytochrome P450 2E1, and flavin-containing mono-oxygenases 2 and 5 were detected in all regions of the human heart and the great vessels. INTERPRETATION: These findings show that expression of genes for cytochrome P450 mono-oxygenases and verapamil metabolism are found predominantly in the right side of the heart. This finding may explain lack of efficacy of certain cardioselective drugs.
BACKGROUND: Cytochrome P450 mono-oxygenases bring about metabolism of many drugs, including verapamil, but no information is available on the metabolism of such drugs in the human heart. METHODS: We investigated the gene expression of major human cytochrome P450 mono-oxygenases in the various regions of explanted hearts from six patients with dilated cardiomyopathy and one with transposition of the arterial trunk. For comparison we also studied samples of liver and lung from three patients and two samples of normal heart. The biological significance of tissue-specific cytochrome mono-oxygenase gene expression was further investigated by study of the microsomal metabolism of verapamil in ventricular tissue. FINDINGS: mRNA for the cytochromes 1A1, 2B6/7, 2C8-19, 2D6, and 4B1 was predominantly expressed in the right ventricle; the unilateral expression of the 2D6 gene in right-venticular tissue is important because of its key role in the metabolism of beta-blockers. A strong correlation between tissue-specific gene expression and enzyme activity was found; microsomal metabolism of verapamil was confined to the right ventricle. By contrast, cytochrome P450 3A genes (which are the major drug-metabolising enzymes in the liver and the lung) were not expressed in any of the human heart tissues, and mRNA transcripts for epoxide hydrolase, cytochrome P450 2E1, and flavin-containing mono-oxygenases 2 and 5 were detected in all regions of the human heart and the great vessels. INTERPRETATION: These findings show that expression of genes for cytochrome P450 mono-oxygenases and verapamil metabolism are found predominantly in the right side of the heart. This finding may explain lack of efficacy of certain cardioselective drugs.
Authors: Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein Journal: Drug Metab Dispos Date: 2007-01-12 Impact factor: 3.922
Authors: Mohammed A Nayeem; Samuel M Poloyac; John R Falck; Darryl C Zeldin; Catherine Ledent; Dovenia S Ponnoth; Habib R Ansari; S Jamal Mustafa Journal: Am J Physiol Heart Circ Physiol Date: 2008-09-19 Impact factor: 4.733
Authors: Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti Journal: Br J Clin Pharmacol Date: 2003-07 Impact factor: 4.335
Authors: Corey E Ventetuolo; Grayson L Baird; R Graham Barr; David A Bluemke; Jason S Fritz; Nicholas S Hill; James R Klinger; Joao A C Lima; Pamela Ouyang; Harold I Palevsky; Amy J Palmisciano; Ipsita Krishnan; Diane Pinder; Ioana R Preston; Kari E Roberts; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2016-05-15 Impact factor: 21.405